Reassessment of the role of induction chemotherapy for head and neck cancer

Lancet Oncology

Volumn 7, Issue 7, 2006, Pages 565-574

  Gibson, Michael K ^a   Forastiere, Arlene A ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; HYDROXYUREA; METHOTREXATE; PACLITAXEL; TAXANE DERIVATIVE; VINCRISTINE;

CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; HEAD AND NECK CANCER; HEAD AND NECK SURGERY; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MEDICAL ASSESSMENT; MEDICAL SPECIALIST; METASTASIS INHIBITION; METHODOLOGY; ONCOLOGY; PATHOLOGICAL ANATOMY; PATIENT SELECTION; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIOLOGIST; REVIEW; SURGEON; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; HEAD AND NECK NEOPLASMS; HUMANS; NEOADJUVANT THERAPY;

EID: 33745268219     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(06)70757-4     Document Type: Review

References (74)

1. In: Fleming I., Cooper J., Henson D., et al. (Eds). American Joint Committee on Cancer Staging Manual. 5th edn. (1997), Lippincott-Raven, Philadelphia, PA
2. Jemal A., Murray T., Ward E., et al. Cancer Statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
3. Carvalho A., Nishimoto I., Califano J., et al. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 114 (2005) 806-816
4. Shiboski C., Schmidt B., and Jordan R. Tongue and tonsil carcinoma: increasing trends in the US population ages 20-44 years. Cancer 103 (2005) 1843-1849
5. Sikora A., Toniolo P., and DeLacure M. The changing demographics of head and neck squamous cell carcinoma in the United States. Laryngoscope 114 (2004) 1915-1923
6. Szentirmay Z., Polus K., Tamas L., et al. Human papillomavirus in head and neck cancer: molecular biology and clinicopathological correlations. Cancer Metastasis Rev 24 (2005) 19-34
7. Gillison M. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 31 (2004) 744-754
8. Gillison M., Koch W., Capone R., et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92 (2000) 709-720
9. Schwartz S., Yueh B., McDougall J., et al. Human papillomavirus infection and survival in oral squamous cell cancer: a population-based study. Otolaryngol Head Neck Surg 125 (2001) 1-9
10. Ang K., Harris J., Garden A., et al. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. J Clin Oncol 23 (2005) 3008-3015
11. Garden A., Harris J., Vokes E., et al. Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 22 (2004) 2856-2864
12. Forastiere A., Koch W., Trotti A., et al. Head and neck cancer. N Engl J Med 345 (2001) 1890-1900
13. Forastiere A., Ang K., Brizel D., et al. Head and neck cancers. J Natl Compr Canc Netw 3 (2005) 316-391
14. Cohen E., Lingen M., and Vokes E. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 22 (2004) 1743-1752
15. Forastiere A. Is there a new role for induction chemotherapy in the treatment of head and neck cancer?. J Natl Cancer Inst 96 (2004) 1647-1650
16. Licitra L., and Vermorken J. Is there still a role for neoadjuvant chemotherapy in head and neck cancer?. Ann Oncol 15 (2004) 7-11
17. Seiwert T., and Cohen E. State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 92 (2005) 1341-1348
18. Domenge C., Hill C., Lefebvre J., et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe dEtude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer 83 (2000) 1594-1598
19. Paccagnella A., Orlando A., Marchiori C., et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 86 (1994) 265-272
20. Zorat P., Paccagnella A., Cavaniglia G., et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst 96 (2004) 1714-1717
21. Lundahl R., Foote R., Bonner J., et al. Combined neck dissection and postoperative radiation therapy in the management of the high-risk neck: a matched-pair analysis. Int J Radiat Oncol Biol Phys 40 (1998) 529-534
22. Bernier J., Cooper J., Pajak T., et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck 27 (2005) 843-850
23. Bernier J., Domenge C., Ozsahin M., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350 (2004) 1945-1952
24. Cooper J., Pajak T., Forastiere A., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous cell carcinoma of the head and neck. N Engl J Med 350 (2004) 1937-1944
25. Jeremic B., Shibamoto Y., Stanisavljevic B., et al. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. Radiother Oncol 43 (1997) 29-37
26. Al-Sarraf M., LeBlanc M., Giri P., et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol 16 (1998) 1310-1317
27. Adelstein D., Li Y., Adams G., et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21 (2003) 92-98
28. Denis F., Garaud P., Bardet E., et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced stage oropharynx carcinoma. J Clin Oncol 22 (2004) 69-76
29. Depondt J., Gehanno P., Martin M., et al. Neoadjuvant chemotherapy with carboplatin/5-fluorouracil in head and neck cancer. Oncology 50 suppl 2 (1993) 23-27
30. Schuller D., Metch B., Stein D., et al. Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group. Laryngoscope 98 (1988) 1205-1211
31. Taylor S., Murthy A., Vannetzel J., et al. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol 12 (1994) 385-395
32. Wee J., Tan E., Tai B., et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol 23 (2005) 6730-6738
33. Jeremic B., Shibamoto Y., Milicic B., et al. Hyperfractionated radiation therapy with or without concurrent low dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 18 (2000) 1458-1464
34. Huguenin P., Beer K., Allal A., et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 22 (2004) 4665-4673
35. Calais G., Alfonsi M., Bardet E., et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced stage oropharynx carcinoma. J Natl Cancer Inst 91 (1999) 2081-2086
36. Seiwert T., and Cohen E. State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 92 (2005) 1341-1348
37. Forastiere A., Goepfert H., Maor M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349 (2003) 2091-2098
38. Pignon J., Bourhis J., Domenge C., et al. Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group-meta-analysis of chemotherapy on head and neck cancer. Lancet 355 (2000) 949-955
39. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324 (1991) 1685-1690
40. Olmi P., Crispino S., Fallai C., et al. Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs accelerated hyperfractionated radiotherapy vs concomitant radiotherapy and chemotherapy-a multicenter randomized trial. Int J Radiat Oncol Biol Phys 55 (2003) 78-92
41. Brockstein B., Haraf D., Rademaker A., et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337 patient, multi-institutional experience. Ann Oncol 15 (2004) 1179-1186
42. Al-Kourainy K., Kish J., Ensley J., et al. Achievement of superior survival for histologically negative versus histologically positive clinically complete responders to cisplatin combination in patients with locally advanced head and neck cancer. Cancer 59 (1987) 233-238
43. Freeman D., Mancuso A., Parsons J., et al. Irradiation alone for supraglottic larynx carcinoma: Can CT findings predict treatment results?. Int J Radiat Oncol Biol Phys 19 (1990) 485-490
44. Lee W., Mancuso A., Saleh E., et al. Can pretreatment computed tomography findings predict local control in T3 squamous cell carcinoma of the glottic larynx treated with radiotherapy alone?. Int J Radiat Oncol Biol Phys 25 (1993) 683-687
45. Nathu R., Mancuso A., Zhu T., et al. The impact of primary tumor volume on local control for oropharyngeal squamous cell carcinoma treated with radiotherapy. Head Neck 22 (2000) 1-5
46. Harrison L., and Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy. Oncologist 9 suppl 5 (2004) 31-40
47. Harrison L., Chadha M., Hill R., et al. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 7 (2002) 492-508
48. Nordsmark M., Overgaard M., and Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 41 (1996) 31-39
49. Harris A. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2 (2002) 38-47
50. Stadler P., Becker A., Feldman H., et al. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Rad Onc Biol Phys 44 (1999) 749-754
51. Dunst J., Stadler P., Becker A., et al. Tumor volume and tumor hypoxia in head and neck cancers. The amount of the hypoxic volume is important. Strahlenther Onkol 179 (2003) 521-526
52. Lehtio K., Eskola O., Viljanen T., et al. Imaging perfusion and hypoxia with PET to predict radiotherapy response in head and neck cancer. Int J Radiat Oncol Biol Phys 59 (2004) 971-982
53. Lehtio K., Oikonen V., Gronroos T., et al. Imaging of blood flow and hypoxia in head and neck cancer: initial evaluation with [(15)O]H(2)O and [(18)F]fluoroerythronitroimidazole PET. J Nucl Med 42 (2001) 1643-1652
54. Licitra L., Grandi C., Guzzo M., et al. Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial. J Clin Oncol 21 (2003) 327-333
55. Vermorken J., Remenar E., van Herpen C., et al. Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): a phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971). Proc Am Soc Clin Oncol 22 14S (2004) 490 (abstr 5508)
56. Hitt R., Lopez-Pousa A., Rodriguez M., et al. Phase III study comparing cisplatin (P) and 5-fluorouracil (F) versus P, F and paclitaxel (T) is induction therapy in locally advanced head & neck cancer (LAHNC). Proc Am Soc Clin Oncol 22 (2003) 496 (abstr 1997)
57. Vokes E., Stenson K., Rosen F., et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 21 (2003) 320-326
58. Haraf D., Rosen F., Stenson K., et al. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res 9 (2003) 5936-5943
59. Posner M., and Lefebvre J. Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck. Br J Cancer 88 (2003) 11-17
60. Haddad R., Colevas A., Tishler R., et al. Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: the Dana Farber Cancer Insitute experience. Cancer 97 (2003) 412-418
61. Schwartz D., Montgomery R., Yueh B., et al. Phase I and initial phase II results from a trial investigating weekly docetaxel and carboplatin given neoadjuvantly and then concurrently with concomitant boost radiotherapy for locally advanced squamous cell carcinoma of the head and neck. Cancer 103 (2005) 2534-2543
62. Janinis J., Papadakou M., Panagos G., et al. Sequential chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil in patients with locally advanced head and neck cancer. Am J Clin Oncol 24 (2001) 227-231
63. Machtay M., Rosenthal D., Hershock D., et al. Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania Phase II Trial. J Clin Oncol 20 (2002) 3964-3971
64. Psyrri A., Kwong M., DiStasio S., et al. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up. J Clin Oncol 22 (2004) 3061-3069
65. Hainsworth J., Meluch A., McClurkan S., et al. Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Cancer J 8 (2002) 311-321
66. Urba S., Moon J., Giri P., et al. Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: a Southwest Oncology Group Trial. J Clin Oncol 23 (2005) 88-95
67. Alvi A., and Johnson J. Development of distant metastases after treatment of advanced stage head and neck cancer. Head Neck 19 (1997) 500-505
68. Adelstein D., Saxton J., Rybicki L., et al. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. J Clin Oncol 24 (2006) 1064-1071
69. Fortin A., Couture C., Doucet R., et al. Does histologic grade have a role in the management of head and neck cancers?. J Clin Oncol 19 (2001) 4107-4116
70. Rubin Grandis J., Melhem M., Barnes E., et al. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 78 (1996) 1284-1292
71. Rubin Grandis J., Melhem M., Gooding W., et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90 (1998) 824-832
72. Bonner J., Harari P., Giralt J., et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 354 (2006) 634-636
73. Temam S., Flahault A., Perie S., et al. p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol 18 (2000) 385-394
74. Cabelguenne A., Blons H., de Waziers I., et al. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol 18 (2000) 1465-1473